肿瘤细胞治疗研究
英文原题：CAR-T cell therapy in Multiple Myeloma: current status and future challenges.
CAR-T cell therapy in Multiple Myeloma: current status and future challenges.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
近年来多发性骨髓瘤的治疗发生了巨大变化，该领域取得了长足进步。
近年来，多发性骨髓瘤治疗发生了巨大变化，并取得显著进步。目前，靶向B细胞成熟抗原（BCMA）的CAR-T 细胞疗法已获批广泛用于复发/难治患者，并正向更早治疗线推进。本综述讨论现行监管审批所依据的证据，并探讨提高CAR-T 疗效的机制和策略，包括应对BCMA丢失、利用或改造免疫抑制性肿瘤微环境、优化细胞制备（包括其他细胞来源的潜在作用）、处理细胞因子释放综合征和神经毒性等安全问题，以及优化患者选择。
The treatment of multiple myeloma has changed dramatically in recent years, with huge strides forward made in the field. Chimeric antigen receptor T-cell therapy targeting the B cell maturation antigen (BCMA) is now widely approved in relapsed refractory patients and is moving into earlier treatment lines. In this review, we discuss the evidence underpinning current regulatory approvals and consider mechanisms through which CAR-T cell efficacy could be improved. These include tackling BCMA-loss, harnessing the immunosuppressive tumour microenvironment, manufacturing concerns including the potential role of other cellular sources, safety issues such as cytokine release syndrome and neurotoxicity, and optimal patient selection.
MEMBER ACCOUNT
登录成功会直接打开下一页。
